503A vs 503B compounded semaglutide: the difference that affects your safety
Two legal compounding categories hide behind one word. What separates them, why the resolved shortage narrowed the rules, and how to verify your source.
Two legal categories, one confusing label
"Compounded" hides a distinction that materially affects oversight. Under the Federal Food, Drug, and Cosmetic Act, compounding lives in two sections. Section 503A covers traditional pharmacy compounding: a licensed pharmacist prepares a medication for an individual patient pursuant to a valid prescription. Section 503B covers outsourcing facilities, which voluntarily register with the FDA, submit to federal inspection, and must follow Current Good Manufacturing Practice (CGMP) — the same quality framework governing conventional drug manufacturing.
The differences that actually matter
| Attribute | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Basis | Individual prescription | Batch, with/without individual scripts |
| FDA registration | State-board licensed | Registers with and inspected by FDA |
| Manufacturing standard | USP compounding standards | CGMP (federal) |
| Batch/stability testing | Variable | More systematic |
| Personalization | High | Lower |
| FDA-approved product? | No | No |
Why the shortage resolution changed everything
During the semaglutide shortage, compounders could produce copies of the commercial drug under shortage provisions, and cheap compounded semaglutide flooded the telehealth market. When the FDA declared the shortage resolved, that broad allowance narrowed: routine copying of the approved product is no longer permitted, and programs generally must rely on clinical-customization pathways. This is the regulatory event behind the market consolidation and the reason provider transparency now matters more than price.
How to read a provider's pharmacy disclosure
Once you understand the distinction, the next skill is reading what a program tells you — and what it conspicuously doesn't. Transparent programs name their pharmacy partner outright, often stating whether it's a 503A or 503B facility, and provide enough detail to verify independently. Vaguer language ("our licensed partner pharmacies") without a name is a signal to slow down. The verification is quick: for a 503A, the state board of pharmacy's online lookup confirms licensure; for a 503B, the FDA publishes a current list of registered outsourcing facilities. What you're really testing is willingness to be accountable — a pharmacy that stands behind its product will tell you who makes it. This is why pharmacy transparency carries heavy weight in our rubric, and refusal to disclose is disqualifying regardless of price.
Frequently asked questions
What is the difference between 503A and 503B compounding?
503A is traditional pharmacy compounding for an individual patient against a prescription under USP standards. 503B outsourcing facilities register with and are inspected by the FDA, follow CGMP standards, and can produce batches. 503B carries more federal oversight; 503A allows more personalization. Neither is FDA-approved.
Is 503B compounded semaglutide safer than 503A?
503B facilities operate under CGMP and FDA inspection, which many clinicians view as stronger manufacturing oversight for injectables. 'Safer' still depends on the specific pharmacy. The key protection either way is a named, verifiable pharmacy with genuine clinical oversight.
Can compounded semaglutide still be made after the shortage ended?
Yes, but under narrower circumstances. With the shortage resolved, routine copying of the approved product is no longer permitted; programs generally rely on clinically personalized formulations.
How do I verify a compounding pharmacy?
For a 503A, verify the license through the state board of pharmacy. For a 503B, confirm the facility on the FDA's registered outsourcing facility list. Always ask the program to name its pharmacy before you pay; refusal is a major red flag.
A pre-purchase verification checklist you can run in ten minutes
Turning the 503A/503B distinction into a decision comes down to a short verification routine that costs nothing and takes about ten minutes before you pay. Start by asking the program a direct question: which pharmacy fills the prescription, and is it a 503A compounding pharmacy or a 503B outsourcing facility? A legitimate program answers plainly; evasion is your first data point. Next, verify the answer. For a named 503A pharmacy, search the relevant state board of pharmacy license lookup to confirm it is licensed and in good standing. For a 503B facility, search the FDA registered outsourcing facility list, which is public and searchable by name. Then check for platform-level signals: LegitScript certification indicates the telehealth service passed a third-party legitimacy review, and a physical business address plus a real prescriber consultation are baseline expectations. Finally, ask what quality testing the pharmacy performs — third-party potency and sterility testing on batches is a meaningful positive signal for an injectable product. Any program selling vials without a prescription, marketing the product as a research chemical, or refusing to name its pharmacy fails the check regardless of price. The finished compounded product still is not FDA-approved either way, so this routine does not make it equivalent to Wegovy or Ozempic — but it cleanly separates programs with genuine accountability from anonymous fulfillment chains, which is the single most important safety distinction a buyer can make on their own.
A pre-purchase verification checklist you can run in ten minutes
Turning the 503A/503B distinction into a decision comes down to a short verification routine that costs nothing and takes about ten minutes before you pay. Start by asking the program a direct question: which pharmacy fills the prescription, and is it a 503A compounding pharmacy or a 503B outsourcing facility? A legitimate program answers plainly; evasion is your first data point. Next, verify the answer. For a named 503A pharmacy, search the relevant state board of pharmacy license lookup to confirm it is licensed and in good standing. For a 503B facility, search the FDA registered outsourcing facility list, which is public and searchable by name. Then check for platform-level signals: LegitScript certification indicates the telehealth service passed a third-party legitimacy review, and a physical business address plus a real prescriber consultation are baseline expectations. Finally, ask what quality testing the pharmacy performs — third-party potency and sterility testing on batches is a meaningful positive signal for an injectable product. Any program selling vials without a prescription, marketing the product as a research chemical, or refusing to name its pharmacy fails the check regardless of price. The finished compounded product still is not FDA-approved either way, so this routine does not make it equivalent to Wegovy or Ozempic — but it cleanly separates programs with genuine accountability from anonymous fulfillment chains, which is the single most important safety distinction a buyer can make on their own.
References
- U.S. FDA. Compounding and the FDA: sections 503A and 503B.
- U.S. FDA. Registered Outsourcing Facilities (503B) list.
- U.S. FDA. Updates on semaglutide shortage status and compounding.
- SemaglutideGLPOne provider verification database, July 2026.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.